Pulmonx (NASDAQ:LUNG) Stock Rating Upgraded by Wall Street Zen

by · The Cerbat Gem

Pulmonx (NASDAQ:LUNG – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other equities analysts have also issued research reports about the stock. Piper Sandler lowered shares of Pulmonx from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $9.00 to $2.50 in a research report on Thursday, July 31st. Citigroup decreased their target price on shares of Pulmonx from $6.50 to $4.15 and set a “neutral” rating on the stock in a research report on Thursday, May 22nd. Stifel Nicolaus dropped their price target on Pulmonx from $16.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 31st. Lake Street Capital reduced their price objective on Pulmonx from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, July 31st. Finally, Wells Fargo & Company decreased their price objective on Pulmonx from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Friday, August 1st. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.66.

View Our Latest Research Report on LUNG

Pulmonx Stock Performance

NASDAQ LUNG opened at $1.71 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.35 and a quick ratio of 4.63. Pulmonx has a 1-year low of $1.47 and a 1-year high of $9.37. The business has a 50 day simple moving average of $2.34 and a two-hundred day simple moving average of $4.29. The stock has a market capitalization of $69.68 million, a PE ratio of -1.20 and a beta of 0.43.

Pulmonx (NASDAQ:LUNG – Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.02. Pulmonx had a negative return on equity of 69.76% and a negative net margin of 62.88%.The business had revenue of $23.86 million for the quarter, compared to analysts’ expectations of $23.46 million. Pulmonx has set its FY 2025 guidance at EPS. On average, research analysts predict that Pulmonx will post -1.55 EPS for the current fiscal year.

Insider Transactions at Pulmonx

In other news, Director Daniel P. Florin purchased 23,321 shares of the business’s stock in a transaction that occurred on Thursday, June 5th. The shares were bought at an average cost of $3.06 per share, for a total transaction of $71,362.26. Following the acquisition, the director owned 117,231 shares of the company’s stock, valued at approximately $358,726.86. This trade represents a 24.83% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Richard Ferrari sold 8,000 shares of the stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $3.16, for a total transaction of $25,280.00. Following the completion of the sale, the director directly owned 87,024 shares in the company, valued at $274,995.84. This trade represents a 8.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors and hedge funds have recently modified their holdings of the business. Deerfield Management Company L.P. Series C purchased a new position in Pulmonx during the 4th quarter valued at $10,421,000. Deutsche Bank AG lifted its position in shares of Pulmonx by 4.2% during the first quarter. Deutsche Bank AG now owns 1,147,105 shares of the company’s stock worth $7,720,000 after purchasing an additional 46,116 shares during the last quarter. Parkman Healthcare Partners LLC boosted its stake in shares of Pulmonx by 194.4% during the first quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company’s stock valued at $4,118,000 after purchasing an additional 404,022 shares during the period. Bank of America Corp DE boosted its stake in shares of Pulmonx by 556.6% during the second quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock valued at $1,246,000 after purchasing an additional 407,971 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Pulmonx by 17.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 408,022 shares of the company’s stock worth $2,770,000 after purchasing an additional 60,489 shares during the last quarter. 91.04% of the stock is owned by institutional investors.

About Pulmonx

(Get Free Report)

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

Featured Articles